Eupraxia Pharmaceuticals is trading at $8.50, up 9.75% in pre-market, with no clear company-specific catalyst identified.
- Its latest release, dated September 30, reported 52-week trial data, including clinical remission maintained by 66% of patients in the highest-dose cohort.
- No October 5 or 6 release appears on the company’s news page.
- Major indices are modestly higher pre-market, but available evidence does not establish that broader market sentiment explains this move.